Revlimid
REVLIMID (lenalidomide) is a prescription medicine used to treat adults with multiple myeloma.
Last updated October 26, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
REVLIMID (lenalidomide) is a prescription medicine used to treat adults with multiple myeloma (MM) in combination with dexamethasone, or as maintenance treatment after autologous hematopoietic stem cell transplantation. It should not be used to treat people who have chronic lymphocytic leukemia (CLL) unless they are participants in a controlled clinical trial. It is not known if REVLIMID is safe and effective in children. The official patient website is intended for US audiences only.
Controversies
2020
Dr. Reddy’s and Celgene settle Revlimid patent litigation
Dr. Reddy’s announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy’s to sell volume-limited generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026.
Recent events
Dr. Reddy’s and Celgene settle Revlimid patent litigation[3]
Reported:
Dr. Reddy’s announced a settlement of its litigation with Celgene over patents for Revlimid capsules. Under the settlement, Celgene agreed to license Dr. Reddy’s to sell volume-limited generic lenalidomide capsules in the U.S. beginning on a confidential date after March 2022, subject to regulatory approval, and without volume limitation beginning January 31, 2026.
- Unconfirmed
FDA expands Revlimid's indication for newly diagnosed multiple myeloma[4]
Reported:
The US Food and Drug Administration expanded the existing indication for Celgene's Revlimid in combination with dexamethasone to include patients newly diagnosed with multiple myeloma.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/revlimid · Editorial policy · How profiles are compiled